首页 > 最新文献

Human Vaccines & Immunotherapeutics最新文献

英文 中文
Politics and confidence toward the COVID-19 vaccination: Points to be considered. 接种 COVID-19 疫苗的政治和信心:需要考虑的问题。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-19 DOI: 10.1080/21645515.2024.2330169
Somsri Wiwanitkit, Viroj Wiwanitkit
{"title":"Politics and confidence toward the COVID-19 vaccination: Points to be considered.","authors":"Somsri Wiwanitkit, Viroj Wiwanitkit","doi":"10.1080/21645515.2024.2330169","DOIUrl":"10.1080/21645515.2024.2330169","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10956620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the impact of the COVID-19 pandemic on perceptions of national scheduled childhood vaccines among Māori and Pacific caregivers, whānau, and healthcare professionals in Aotearoa New Zealand. 探索 COVID-19 大流行对新西兰奥特亚罗瓦毛利人和太平洋地区护理人员、毛利人以及医疗保健专业人员对国家儿童计划疫苗的看法的影响。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-01-11 DOI: 10.1080/21645515.2023.2301626
Nadia A Charania, Daysha Tonumaipe'a, Te Wai Barbarich-Unasa, Leon Iusitini, Georgina Davis, Gail Pacheco, Denise Wilson

In Aotearoa New Zealand, there has been a marked decrease in the uptake of routine childhood vaccinations since the onset of the COVID-19 pandemic, particularly among Māori and Pacific children. This Māori and Pacific-centered research used an interpretive description methodology. We undertook culturally informed interviews and discussions with Māori and Pacific caregivers (n = 24) and healthcare professionals (n = 13) to understand their perceptions of routine childhood vaccines. Data were analyzed using reflexive thematic analysis and privileged respective Māori and Pacific worldviews. Four themes were constructed. "We go with the norm" reflected how social norms, health personnel and institutions promoted (and sometimes coerced) participants' acceptance of routine vaccines before the pandemic. "Everything became difficult" explains how the pandemic added challenges to the daily struggles of whānau (extended family networks) and healthcare professionals. Participants noted how information sources influenced disease and vaccine perceptions and health behaviors. "It needed to have an ethnic-specific approach" highlighted the inappropriateness of Western-centric strategies that dominated during the initial pandemic response that did not meet the needs of Māori and Pacific communities. Participants advocated for whānau-centric vaccination efforts. "People are now finding their voice" expressed renewed agency among whānau about vaccination following the immense pressure to receive COVID-19 vaccines. The pandemic created an opportune time to support informed parental vaccine decision-making in a manner that enhances the mana (authority, control) of whānau. Māori and Pacific-led vaccination strategies should be embedded in immunization service delivery to improve uptake and immunization experiences for whānau.

在新西兰奥特亚罗瓦,自 COVID-19 大流行以来,儿童常规疫苗接种率明显下降,特别是在毛利族和太平洋裔儿童中。这项以毛利人和太平洋裔人为中心的研究采用了解释性描述方法。我们对毛利族和太平洋岛屿族裔的护理人员(24 人)和医疗保健专业人员(13 人)进行了有文化背景的访谈和讨论,以了解他们对常规儿童疫苗的看法。我们采用反思性主题分析法对数据进行了分析,并对毛利人和太平洋岛民各自的世界观进行了优选。共构建了四个主题。"我们遵循规范 "反映了社会规范、卫生人员和机构如何在大流行之前促进(有时是强迫)参与者接受常规疫苗。"一切都变得困难重重 "解释了大流行如何给大家庭网络和医疗保健专业人员的日常工作增加了挑战。与会者指出,信息来源如何影响人们对疾病和疫苗的认识以及健康行为。"需要采取针对特定种族的方法 "强调了以西方为中心的战略的不适宜性,这种战略在最初的大流行应对措施中占主导地位,不能满足毛利人和太平洋裔社区的需求。与会者主张开展以毛利人为中心的疫苗接种工作。"人们现在找到了自己的声音",这表达了在接种 COVID-19 疫苗的巨大压力下,毛利人对疫苗接种的重新认同。这次大流行为支持家长在知情的情况下做出疫苗接种决策创造了有利时机,从而增强了毛利人的mana(权威、控制)。毛利人和太平洋岛屿族裔主导的疫苗接种战略应纳入免疫接种服务中,以提高毛利人的接种率和免疫接种体验。
{"title":"Exploring the impact of the COVID-19 pandemic on perceptions of national scheduled childhood vaccines among Māori and Pacific caregivers, whānau, and healthcare professionals in Aotearoa New Zealand.","authors":"Nadia A Charania, Daysha Tonumaipe'a, Te Wai Barbarich-Unasa, Leon Iusitini, Georgina Davis, Gail Pacheco, Denise Wilson","doi":"10.1080/21645515.2023.2301626","DOIUrl":"10.1080/21645515.2023.2301626","url":null,"abstract":"<p><p>In Aotearoa New Zealand, there has been a marked decrease in the uptake of routine childhood vaccinations since the onset of the COVID-19 pandemic, particularly among Māori and Pacific children. This Māori and Pacific-centered research used an interpretive description methodology. We undertook culturally informed interviews and discussions with Māori and Pacific caregivers (<i>n</i> = 24) and healthcare professionals (<i>n</i> = 13) to understand their perceptions of routine childhood vaccines. Data were analyzed using reflexive thematic analysis and privileged respective Māori and Pacific worldviews. Four themes were constructed. \"<i>We go with the norm</i>\" reflected how social norms, health personnel and institutions promoted (and sometimes coerced) participants' acceptance of routine vaccines before the pandemic. <i>\"Everything became difficult\"</i> explains how the pandemic added challenges to the daily struggles of whānau (extended family networks) and healthcare professionals. Participants noted how information sources influenced disease and vaccine perceptions and health behaviors. <i>\"It needed to have an ethnic-specific approach\"</i> highlighted the inappropriateness of Western-centric strategies that dominated during the initial pandemic response that did not meet the needs of Māori and Pacific communities. Participants advocated for whānau-centric vaccination efforts. <i>\"People are now finding their voice\"</i> expressed renewed agency among whānau about vaccination following the immense pressure to receive COVID-19 vaccines. The pandemic created an opportune time to support informed parental vaccine decision-making in a manner that enhances the mana (authority, control) of whānau. Māori and Pacific-led vaccination strategies should be embedded in immunization service delivery to improve uptake and immunization experiences for whānau.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial. 成人在接种季节性四价流感疫苗的同时接种 COVID-19 mRNA-1273 强化疫苗不会产生免疫干扰或安全性问题:随机试验。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-21 DOI: 10.1080/21645515.2024.2327736
Abdi Naficy, Adrienne Kuxhausen, Harry Seifert, Andrew Hastie, Brett Leav, Jacqueline Miller, Kate Anteyi, Agnes Mwakingwe-Omari

The objective of the study was to assess the safety and immunogenicity of mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal quadrivalent influenza vaccine (QIV). This was a phase 3, randomized, open-label study. Eligible adults aged ≥ 18 years were randomly assigned (1:1) to receive mRNA-1273 (50 µg) booster vaccination and QIV 2 weeks apart (Seq group) or concomitantly (Coad group). Primary objectives were non-inferiority of haemagglutinin inhibition (HI) and anti-Spike protein antibody responses in the Coad compared to Seq group. 497/498 participants were randomized and vaccinated in the Seq/Coad groups, respectively. The adjusted geometric mean titer/concentration ratios (95% confidence intervals) (Seq/Coad) for HI antibodies were 1.02 (0.89-1.18) for A/H1N1, 0.93 (0.82-1.05) for A/H3N2, 1.00 (0.89-1.14] for B/Victoria, and 1.04 (0.93-1.17) for B/Yamagata; and 0.98 (0.84-1.13) for anti-Spike antibodies, thus meeting the protocol-specified non-inferiority criteria. The most frequently reported adverse events in both groups were pain at the injection site and myalgia. The 2 groups were similar in terms of the overall frequency, intensity, and duration of adverse events. In conclusion, co-administration of mRNA-1273 booster vaccine with QIV in adults was immunologically non-inferior to sequential administration. Safety and reactogenicity profiles were similar in both groups (clinicaltrials.gov NCT05047770).

这项研究的目的是评估mRNA-1273 COVID-19强化疫苗与蛋基标准剂量季节性四价流感疫苗(QIV)联合接种时的安全性和免疫原性。这是一项 3 期随机开放标签研究。年龄≥18岁的合格成人被随机分配(1:1)接种mRNA-1273(50微克)强化疫苗和QIV,接种间隔为2周(Seq组)或同时接种(Coad组)。主要目标是Coad组与Seq组相比,血凝素抑制(HI)和抗斯派克蛋白抗体反应无劣效。Seq/Coad组分别有497/498名参与者被随机分配并接种疫苗。调整后的 HI 抗体几何平均滴度/浓度比(95% 置信区间)(Seq/Coad)分别为:A/H1N1:1.02(0.89-1.18);A/H3N2:0.93(0.82-1.05);A/H3N2:1.00(0.89-1.14),B/山形为1.04(0.93-1.17);抗穗抗体为0.98(0.84-1.13),因此符合方案规定的非劣效性标准。两组最常报告的不良反应是注射部位疼痛和肌痛。就不良反应的总体频率、强度和持续时间而言,两组相似。总之,在成人中将 mRNA-1273 强化疫苗与 QIV 联合接种在免疫学上并不劣于连续接种。两组的安全性和反应性特征相似(clinicaltrials.gov NCT05047770)。
{"title":"No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.","authors":"Abdi Naficy, Adrienne Kuxhausen, Harry Seifert, Andrew Hastie, Brett Leav, Jacqueline Miller, Kate Anteyi, Agnes Mwakingwe-Omari","doi":"10.1080/21645515.2024.2327736","DOIUrl":"10.1080/21645515.2024.2327736","url":null,"abstract":"<p><p>The objective of the study was to assess the safety and immunogenicity of mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal quadrivalent influenza vaccine (QIV). This was a phase 3, randomized, open-label study. Eligible adults aged ≥ 18 years were randomly assigned (1:1) to receive mRNA-1273 (50 µg) booster vaccination and QIV 2 weeks apart (Seq group) or concomitantly (Coad group). Primary objectives were non-inferiority of haemagglutinin inhibition (HI) and anti-Spike protein antibody responses in the Coad compared to Seq group. 497/498 participants were randomized and vaccinated in the Seq/Coad groups, respectively. The adjusted geometric mean titer/concentration ratios (95% confidence intervals) (Seq/Coad) for HI antibodies were 1.02 (0.89-1.18) for A/H1N1, 0.93 (0.82-1.05) for A/H3N2, 1.00 (0.89-1.14] for B/Victoria, and 1.04 (0.93-1.17) for B/Yamagata; and 0.98 (0.84-1.13) for anti-Spike antibodies, thus meeting the protocol-specified non-inferiority criteria. The most frequently reported adverse events in both groups were pain at the injection site and myalgia. The 2 groups were similar in terms of the overall frequency, intensity, and duration of adverse events. In conclusion, co-administration of mRNA-1273 booster vaccine with QIV in adults was immunologically non-inferior to sequential administration. Safety and reactogenicity profiles were similar in both groups (clinicaltrials.gov NCT05047770).</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic. COVID-19大流行期间中国东部地区百日咳毒素和丝状血凝素免疫球蛋白G抗体的血清流行病学研究。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-22 DOI: 10.1080/21645515.2024.2331438
Xiang Sun, Tingting Zhang, Jinning Sun, Juan Zhou, Qiang Chen, Chengmei Jia, Yan Xu, Yun Wu, Zhiguo Wang, Wen Wang

This study employed sero-epidemiological methods to estimate the incidence of pertussis within a healthy population located in eastern China. The aim was to gain deeper insights into the epidemiological characteristics and burden of pertussis within the country. Blood samples were collected from healthy individuals in Jiangsu Province between June 2019 and December 2022. The levels of IgG antibodies against pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) in the serum were quantitatively measured using enzyme-linked immunosorbent assay (ELISA). Additionally, pertussis case data reported in Jiangsu Province were collected from the China Information System for Disease Control and Prevention and compared with the results of this study. In 2022, the reported incidence of pertussis stood at 1.0 per 100,000 individuals, marking the highest rate observed in the past two decades. Among 1,909 patients examined, the geometric mean concentration (GMC) of anti-PT IgG antibody was 20.2 (18.5-21.9) IU/ml, while that of anti-FHA IgG antibody was 27.0 (25.4-28.7) IU/ml. The IgG-PT and IgG-FHA seropositivity rate (>20.0 IU/ml) was highest in the 1 ~ 2 y old group and decreased rapidly to the lowest in the 3 ~ 4 y old group and then increased gradually with age. The estimated rate of pertussis infection based on seroprevalence was approximately 25,625-fold higher than the reported notification rate in the ≥15 year age group. Our findings highlight decreased immunity post-vaccination, stressing the importance of additional booster shots for adolescents and adults to maintain immunity and reduce severe illness. Additionally, they offer vital guidance for policymakers to enhance immunization strategies.

本研究采用血清流行病学方法对中国东部健康人群的百日咳发病率进行了估计。目的是更深入地了解百日咳在中国的流行病学特征和负担。研究人员在2019年6月至2022年12月期间采集了江苏省健康人群的血样。采用酶联免疫吸附试验(ELISA)定量检测血清中百日咳毒素(抗-PT)和丝状血凝素(抗-FHA)的IgG抗体水平。此外,研究人员还从中国疾病预防控制信息系统中收集了江苏省的百日咳病例数据,并将其与本研究结果进行了比较。2022年,百日咳的报告发病率为每10万人1.0例,是近二十年来观察到的最高发病率。在接受检查的 1909 名患者中,抗 PT IgG 抗体的几何平均浓度(GMC)为 20.2(18.5-21.9)IU/ml,而抗 FHA IgG 抗体的几何平均浓度(GMC)为 27.0(25.4-28.7)IU/ml。IgG-PT和IgG-FHA血清阳性率(>20.0 IU/ml)在1~2岁组最高,在3~4岁组迅速降至最低,然后随着年龄的增长而逐渐升高。根据血清流行率估计的百日咳感染率比报告的≥15 岁年龄组的感染率高出约 25 625 倍。我们的研究结果突显了接种疫苗后免疫力下降的问题,强调了青少年和成年人接种更多加强针剂以保持免疫力和减少重症的重要性。此外,这些结果还为政策制定者加强免疫策略提供了重要指导。
{"title":"The seroepidemiology of immunoglobulin G antibodies against pertussis toxin and filamentous hemagglutinin in the east of China during the COVID-19 pandemic.","authors":"Xiang Sun, Tingting Zhang, Jinning Sun, Juan Zhou, Qiang Chen, Chengmei Jia, Yan Xu, Yun Wu, Zhiguo Wang, Wen Wang","doi":"10.1080/21645515.2024.2331438","DOIUrl":"10.1080/21645515.2024.2331438","url":null,"abstract":"<p><p>This study employed sero-epidemiological methods to estimate the incidence of pertussis within a healthy population located in eastern China. The aim was to gain deeper insights into the epidemiological characteristics and burden of pertussis within the country. Blood samples were collected from healthy individuals in Jiangsu Province between June 2019 and December 2022. The levels of IgG antibodies against pertussis toxin (anti-PT) and filamentous hemagglutinin (anti-FHA) in the serum were quantitatively measured using enzyme-linked immunosorbent assay (ELISA). Additionally, pertussis case data reported in Jiangsu Province were collected from the China Information System for Disease Control and Prevention and compared with the results of this study. In 2022, the reported incidence of pertussis stood at 1.0 per 100,000 individuals, marking the highest rate observed in the past two decades. Among 1,909 patients examined, the geometric mean concentration (GMC) of anti-PT IgG antibody was 20.2 (18.5-21.9) IU/ml, while that of anti-FHA IgG antibody was 27.0 (25.4-28.7) IU/ml. The IgG-PT and IgG-FHA seropositivity rate (>20.0 IU/ml) was highest in the 1 ~ 2 y old group and decreased rapidly to the lowest in the 3 ~ 4 y old group and then increased gradually with age. The estimated rate of pertussis infection based on seroprevalence was approximately 25,625-fold higher than the reported notification rate in the ≥15 year age group. Our findings highlight decreased immunity post-vaccination, stressing the importance of additional booster shots for adolescents and adults to maintain immunity and reduce severe illness. Additionally, they offer vital guidance for policymakers to enhance immunization strategies.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HV&I Reviewer Highlight. HV&I 评审员亮点。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-27 DOI: 10.1080/21645515.2024.2333691
Ronald Ellis, Adam Weiss
{"title":"HV&I Reviewer Highlight.","authors":"Ronald Ellis, Adam Weiss","doi":"10.1080/21645515.2024.2333691","DOIUrl":"10.1080/21645515.2024.2333691","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10978018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with HPV vaccine hesitancy among college students: A cross-sectional survey based on 3Cs and structural equation model in China. 大学生对 HPV 疫苗犹豫不决的相关因素:基于3C和结构方程模型的中国横断面调查。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-02-05 DOI: 10.1080/21645515.2024.2309731
Cheng Chen, Ting Chen, Mingzhao Huang, Yan Huang, Luying Zhang, Pindong Li

Despite the high effectiveness of HPV vaccines in preventing infection, vaccine hesitancy remains a concern, particularly in China. This study aimed to explore college students' attitudes toward HPV vaccination and identify associated factors. Data was collected through a cross-sectional survey using self-administered questionnaires in four cities from May to June 2022. Chi-square tests and logistic regression analyses were conducted to identify factors. Additionally, an integrated structural equation model (SEM) based on the 3Cs (confidence, convenience, complacency) was developed to understand underlying factors contributing to hesitancy. The results from 2261 valid questionnaires were enlightening. A significant 89.47% (59.4% for females) considered HPV vaccination necessary, with 9.82% remaining neutral and only 0.71% deeming it unnecessary. Factors like higher education, being a medical student, residing in urban areas, having medical insurance, more extraordinary living expenses, a family history of tumors, and a solid understanding of HPV played a role in perceiving the vaccine as necessary. Among the 1438 female respondents, 84.36% had no hesitancy toward HPV vaccination, 13.53% expressed hesitancy, and 2.11% refused vaccination. Factors like age, understanding of HPV, medical staff recommendations, living expenses, and family history influenced hesitancy levels. SEM revealed that the 3Cs significantly affected vaccine hesitancy. Factors like price, booking process, vaccination times, trust in vaccines, medical staff recommendations, efficiency, and risk perception collectively influenced hesitancy. In conclusion, this study found high acceptance of HPV vaccination but acknowledged the complexity of hesitancy factors. It recommends medical staff disseminate scientific knowledge, offer recommendations, simplify booking procedures, and expand vaccination sites to address vaccine hesitancy effectively.

尽管 HPV 疫苗在预防感染方面效果显著,但疫苗接种犹豫仍是一个令人担忧的问题,尤其是在中国。本研究旨在探讨大学生对接种HPV疫苗的态度,并找出相关因素。研究于 2022 年 5 月至 6 月在四个城市通过自填问卷的方式进行横断面调查,收集数据。研究采用了卡方检验和逻辑回归分析来确定相关因素。此外,还建立了一个基于 3C(自信、便利、自满)的综合结构方程模型(SEM),以了解导致犹豫不决的潜在因素。2261 份有效问卷的结果很有启发性。89.47%的受访者(女性占 59.4%)认为有必要接种人乳头瘤病毒疫苗,9.82%的受访者持中立态度,只有 0.71%的受访者认为没有必要。高学历、医学生、居住在城市地区、有医疗保险、生活费用较高、有肿瘤家族史、对 HPV 有深入了解等因素在认为有必要接种疫苗方面起到了一定的作用。在 1438 名女性受访者中,84.36% 对接种 HPV 疫苗没有犹豫,13.53% 表示犹豫,2.11% 拒绝接种。年龄、对 HPV 的了解程度、医务人员的建议、生活费用和家族病史等因素影响了受访者的犹豫程度。SEM 显示,3C 显著影响疫苗接种的犹豫程度。价格、预约流程、接种时间、对疫苗的信任、医务人员的建议、效率和风险意识等因素共同影响了犹豫程度。总之,这项研究发现,人们对 HPV 疫苗接种的接受度很高,但也承认犹豫因素的复杂性。研究建议医务人员传播科学知识、提供建议、简化预约程序并扩大接种点,以有效解决疫苗接种犹豫不决的问题。
{"title":"Factors associated with HPV vaccine hesitancy among college students: A cross-sectional survey based on 3Cs and structural equation model in China.","authors":"Cheng Chen, Ting Chen, Mingzhao Huang, Yan Huang, Luying Zhang, Pindong Li","doi":"10.1080/21645515.2024.2309731","DOIUrl":"10.1080/21645515.2024.2309731","url":null,"abstract":"<p><p>Despite the high effectiveness of HPV vaccines in preventing infection, vaccine hesitancy remains a concern, particularly in China. This study aimed to explore college students' attitudes toward HPV vaccination and identify associated factors. Data was collected through a cross-sectional survey using self-administered questionnaires in four cities from May to June 2022. Chi-square tests and logistic regression analyses were conducted to identify factors. Additionally, an integrated structural equation model (SEM) based on the 3Cs (confidence, convenience, complacency) was developed to understand underlying factors contributing to hesitancy. The results from 2261 valid questionnaires were enlightening. A significant 89.47% (59.4% for females) considered HPV vaccination necessary, with 9.82% remaining neutral and only 0.71% deeming it unnecessary. Factors like higher education, being a medical student, residing in urban areas, having medical insurance, more extraordinary living expenses, a family history of tumors, and a solid understanding of HPV played a role in perceiving the vaccine as necessary. Among the 1438 female respondents, 84.36% had no hesitancy toward HPV vaccination, 13.53% expressed hesitancy, and 2.11% refused vaccination. Factors like age, understanding of HPV, medical staff recommendations, living expenses, and family history influenced hesitancy levels. SEM revealed that the 3Cs significantly affected vaccine hesitancy. Factors like price, booking process, vaccination times, trust in vaccines, medical staff recommendations, efficiency, and risk perception collectively influenced hesitancy. In conclusion, this study found high acceptance of HPV vaccination but acknowledged the complexity of hesitancy factors. It recommends medical staff disseminate scientific knowledge, offer recommendations, simplify booking procedures, and expand vaccination sites to address vaccine hesitancy effectively.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10854271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of vaccine literacy and health literacy in the health prevention decision-making process. 疫苗知识和健康知识在健康预防决策过程中的作用。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-06 DOI: 10.1080/21645515.2024.2321675
Claudia Isonne, Carolina Marzuillo, Paolo Villari, Valentina Baccolini
{"title":"The role of vaccine literacy and health literacy in the health prevention decision-making process.","authors":"Claudia Isonne, Carolina Marzuillo, Paolo Villari, Valentina Baccolini","doi":"10.1080/21645515.2024.2321675","DOIUrl":"10.1080/21645515.2024.2321675","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140040698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human vaccines and immunotherapeutics: News December 2023. 人类疫苗和免疫疗法:2023 年 12 月新闻。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-01-17 DOI: 10.1080/21645515.2024.2305025
Ronald Ellis, Adam Weiss
{"title":"Human vaccines and immunotherapeutics: News December 2023.","authors":"Ronald Ellis, Adam Weiss","doi":"10.1080/21645515.2024.2305025","DOIUrl":"10.1080/21645515.2024.2305025","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seroprevalence of IgG antibodies against pertussis toxin in the Chinese population: A systematic review and meta-analysis. 中国人群百日咳毒素 IgG 抗体的血清流行率:系统回顾和荟萃分析。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-05-02 DOI: 10.1080/21645515.2024.2341454
Yao Zhu, Wanting Zhang, Jie Hu, Shuying Luo, Yang Zhou, Xuewen Tang, Rui Yan, Xuan Deng, Hanqing He

Pertussis is a vaccine-preventable infectious disease; however, data on pertussis antibody levels in a nationwide population are still limited in China. We aimed to pool the seropositivity rates of IgG antibodies against pertussis toxin (PT-IgG) across the country. We systematically searched PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure Database for studies published between January 1, 2010, and June 30, 2023. Studies reporting the seroprevalence of PT-IgG among a healthy Chinese population were included. Pooled estimates were obtained using random-effects meta-analyzes. The meta-analysis included 39 studies (47,778 participants) reporting anti-PT IgG seropositivity rates. The pooled rate for all ages was 7.06% (95% CI, 5.50%-9.07%). Subgroup analyzes showed rates ranging from 6.36% to 12.50% across different age groups. This meta-analysis indicated a low anti-PT IgG seropositivity rate in the Chinese population, particularly among school-aged children and young adults. This finding underscores the urgent need to refine immunization strategies.

百日咳是一种可通过接种疫苗预防的传染病,但在中国,有关全国人群百日咳抗体水平的数据仍然有限。我们旨在汇总全国百日咳毒素 IgG 抗体(PT-IgG)的血清阳性率。我们系统检索了 PubMed、Web of Science、Embase 和中国国家知识基础设施数据库中 2010 年 1 月 1 日至 2023 年 6 月 30 日期间发表的研究。纳入的研究报告了 PT-IgG 在中国健康人群中的血清流行率。采用随机效应荟萃分析得出汇总估计值。荟萃分析共纳入 39 项研究(47778 名参与者),报告了抗 PT IgG 血清阳性率。所有年龄段的汇总率为 7.06%(95% CI,5.50%-9.07%)。亚组分析显示,不同年龄组的比率从 6.36% 到 12.50% 不等。这项荟萃分析表明,中国人群的抗 PT IgG 血清阳性率较低,尤其是学龄儿童和年轻人。这一发现凸显了完善免疫策略的迫切性。
{"title":"Seroprevalence of IgG antibodies against pertussis toxin in the Chinese population: A systematic review and meta-analysis.","authors":"Yao Zhu, Wanting Zhang, Jie Hu, Shuying Luo, Yang Zhou, Xuewen Tang, Rui Yan, Xuan Deng, Hanqing He","doi":"10.1080/21645515.2024.2341454","DOIUrl":"https://doi.org/10.1080/21645515.2024.2341454","url":null,"abstract":"<p><p>Pertussis is a vaccine-preventable infectious disease; however, data on pertussis antibody levels in a nationwide population are still limited in China. We aimed to pool the seropositivity rates of IgG antibodies against pertussis toxin (PT-IgG) across the country. We systematically searched PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure Database for studies published between January 1, 2010, and June 30, 2023. Studies reporting the seroprevalence of PT-IgG among a healthy Chinese population were included. Pooled estimates were obtained using random-effects meta-analyzes. The meta-analysis included 39 studies (47,778 participants) reporting anti-PT IgG seropositivity rates. The pooled rate for all ages was 7.06% (95% CI, 5.50%-9.07%). Subgroup analyzes showed rates ranging from 6.36% to 12.50% across different age groups. This meta-analysis indicated a low anti-PT IgG seropositivity rate in the Chinese population, particularly among school-aged children and young adults. This finding underscores the urgent need to refine immunization strategies.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11067989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits, challenges, and strategies related to using presumptive recommendations for HPV vaccination: A qualitative study with rural and non-rural-serving primary care professionals. 与使用 HPV 疫苗接种推定建议相关的益处、挑战和策略:一项针对农村和非农村初级保健专业人员的定性研究。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-05-06 DOI: 10.1080/21645515.2024.2347018
Olufeyisayo O Odebunmi, Lisa P Spees, Caitlin B Biddell, Tatenda Yemeke, Juan Yanguela, Colleen Higgins, Melissa Gilkey, Sachiko Ozawa, Stephanie B Wheeler

HPV vaccination coverage remains far below the national target of 80% among US adolescents, particularly in rural areas, which have vaccine uptake rates that are 10% points lower than non-rural areas on average. Primary care professionals (PCPs) can increase coverage by using presumptive recommendations to introduce HPV vaccination in a way that assumes parents want to vaccinate. Through semi-structured interviews, we explored PCPs' experiences and perceptions of using presumptive recommendations in rural- and non-rural-serving primary care clinics in North Carolina. Thematic analysis revealed that most PCPs in rural and non-rural contexts used presumptive recommendations and felt the strategy was an effective and concise way to introduce the topic of HPV vaccination to parents. At the same time, some PCPs raised concerns about presumptive recommendations potentially straining relationships with certain parents, including those who had previously declined HPV vaccine or who distrust medical authority due to their past experiences with the healthcare system. PCPs dealt with these challenges by using a more open-ended approach when introducing HPV vaccination to parents. In conclusion, our findings suggest that PCPs in both rural and non-rural settings see value in using presumptive recommendations to introduce HPV vaccination, but to adequately address concerns and ensure increased HPV vaccine uptake, PCPs can use simple and culturally sensitive language to ensure fully informed consent and to maintain parental trust. And to further strengthen HPV vaccine discussions, PCPs can utilize other effective HPV communication techniques, like the Announcement Approach, in discussing HPV vaccinations with hesitant parents.

在美国青少年中,HPV 疫苗接种率仍远低于 80% 的国家目标,尤其是在农村地区,疫苗接种率比非农村地区平均低 10%。初级保健专业人员(PCPs)可以通过使用推定建议的方式提高疫苗接种率,这种方式假定家长愿意接种疫苗。通过半结构式访谈,我们探讨了北卡罗来纳州农村和非农村初级保健诊所的初级保健医生使用推定建议的经验和看法。主题分析表明,农村和非农村地区的大多数初级保健医生都使用了推定建议,并认为该策略是向家长介绍 HPV 疫苗接种主题的一种有效而简洁的方式。与此同时,一些初级保健医生担心推定建议可能会使他们与某些家长的关系变得紧张,其中包括那些之前拒绝接受 HPV 疫苗接种的家长,或者那些由于过去在医疗系统中的经历而不信任医疗权威的家长。为了应对这些挑战,初级保健医生在向家长介绍 HPV 疫苗接种时采用了更加开放的方式。总之,我们的研究结果表明,农村和非农村地区的初级保健医生都认为使用推定建议来介绍 HPV 疫苗接种很有价值,但为了充分消除顾虑并确保提高 HPV 疫苗的接种率,初级保健医生可以使用简单且具有文化敏感性的语言来确保完全知情同意并保持家长的信任。为了进一步加强对 HPV 疫苗的讨论,初级保健医生在与犹豫不决的家长讨论 HPV 疫苗接种问题时,可以利用其他有效的 HPV 沟通技巧,如 "公告法"。
{"title":"Benefits, challenges, and strategies related to using presumptive recommendations for HPV vaccination: A qualitative study with rural and non-rural-serving primary care professionals.","authors":"Olufeyisayo O Odebunmi, Lisa P Spees, Caitlin B Biddell, Tatenda Yemeke, Juan Yanguela, Colleen Higgins, Melissa Gilkey, Sachiko Ozawa, Stephanie B Wheeler","doi":"10.1080/21645515.2024.2347018","DOIUrl":"10.1080/21645515.2024.2347018","url":null,"abstract":"<p><p>HPV vaccination coverage remains far below the national target of 80% among US adolescents, particularly in rural areas, which have vaccine uptake rates that are 10% points lower than non-rural areas on average. Primary care professionals (PCPs) can increase coverage by using presumptive recommendations to introduce HPV vaccination in a way that assumes parents want to vaccinate. Through semi-structured interviews, we explored PCPs' experiences and perceptions of using presumptive recommendations in rural- and non-rural-serving primary care clinics in North Carolina. Thematic analysis revealed that most PCPs in rural and non-rural contexts used presumptive recommendations and felt the strategy was an effective and concise way to introduce the topic of HPV vaccination to parents. At the same time, some PCPs raised concerns about presumptive recommendations potentially straining relationships with certain parents, including those who had previously declined HPV vaccine or who distrust medical authority due to their past experiences with the healthcare system. PCPs dealt with these challenges by using a more open-ended approach when introducing HPV vaccination to parents. In conclusion, our findings suggest that PCPs in both rural and non-rural settings see value in using presumptive recommendations to introduce HPV vaccination, but to adequately address concerns and ensure increased HPV vaccine uptake, PCPs can use simple and culturally sensitive language to ensure fully informed consent and to maintain parental trust. And to further strengthen HPV vaccine discussions, PCPs can utilize other effective HPV communication techniques, like the Announcement Approach, in discussing HPV vaccinations with hesitant parents.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11085946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Vaccines & Immunotherapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1